Tarsus Pharmaceuticals spent the second quarter proving that a single category-creating eye drop can fund a multi-asset franchise, then immediately spent that proof on two retina acquisitions. XDEMVY remains the first approved therapy for Demodex blepharitis, an eyelid disease that sat in plain sight for decades, and the commercial print still shows accelerating demand rather than a launch that is rolling over. The investment debate is no longer whether the drop works in the market. It is whether management can convert that cash engine into a durable eye-care platform without starving the franchise that pays for everything else.
Net product sales reached $173.9 million in the quarter, a year-over-year jump that management used as permission to raise the full-year outlook. At the same time, selling costs and research spending both climbed sharply, and the company still posted a net loss. The deeper tension sits off the income statement entirely. Tarsus closed the iRenix Medical purchase to enter retina with an investigational ocular antiseptic, then agreed to buy Alkeus Pharmaceuticals for an upfront package of cash and stock that dwarfs a typical tuck-in, and filled part of the hole with a $125 million private placement. Category cash is being recycled into assets whose first registrational readouts sit years away.
The next several quarters resolve a narrower question than the promotional language implies. If XDEMVY keeps compounding through the second half inside the raised sales band, the core franchise can absorb the Alkeus cash outlay and still leave a path toward profitability next year. If depth of prescribing stalls while research and integration costs step up, the equity is paying a platform multiple for what is still a one-product company. Does the market get a second commercial engine, or a more expensive version of the first?